title: A rare case of primary choriocarcinoma in the sigmoid colon.
abstract: Primary colorectal choriocarcinoma is an extremely rare neoplasm and is usually associated with a poor prognosis. Only 13 cases of colorectal choriocarcinoma have previously been reported. There is no standard chemotherapeutic regimen for this tumor type. A 68-year-old man presented with melena and was diagnosed with sigmoid colonic adenocarcinoma with multiple liver metastases. He underwent a laparoscopic sigmoidectomy. Pathology revealed choriocarcinoma with a focal component of moderately differentiated adenocarcinoma of colon origin. Based on the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) results, mFOLFOX6 and bevacizumab were administered, which suppressed aggressive tumor growth for 4 mo. The patient died 9 mo after the initial diagnosis. Our study results suggest that the standard chemotherapy regimen for colorectal cancer might have suppressive effects against primary colorectal choriocarcinoma. Moreover, CD-DST may provide, at least in part, therapeutic insight for the selection of appropriate antitumor agents for such patients.
authors.affiliation: Hiromitsu Maehira, Tomoharu Shimizu, Hiromichi Sonoda, Eiji Mekata, Tomoharo Yamaguchi, Tohru Miyake, Tohru Tani, Department of Surgery, Shiga University of Medical Science, Shiga 520-2192, Japan.
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Maehira
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Shimizu
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Sonoda
authors.forename: Eiji
authors.initials: E
authors.lastname: Mekata
authors.forename: Tomoharo
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Tohru
authors.initials: T
authors.lastname: Miyake
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Ishida
authors.forename: Tohru
authors.initials: T
authors.lastname: Tani
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D001706:Biopsy; D017024:Chemotherapy, Adjuvant; D031954:Choriocarcinoma, Non-gestational / Q000150:complications / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D003082:Colectomy; D003113:Colonoscopy; D018450:Disease Progression; D004354:Drug Screening Assays, Antitumor; D017809:Fatal Outcome; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008551:Melena / Q000209:etiology; D018193:Neoplasms, Complex and Mixed / Q000150:complications / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D012811:Sigmoid Neoplasms / Q000150:complications / Q000473:pathology* / Q000628:therapy; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
keywords: Chemotherapy; Choriocarcinoma; Colon cancer; Colorectal cancer; Culture drug sensitivity test